Aging and Rejuvenation Knowledge Gaps

Last Updated: 2026-03-15 PT

Overview

Aging is the single greatest risk factor for virtually all neurodegenerative diseases. While age-associated decline in cellular senescence, proteostasis, mitochondrial function, and neuroinflammation are well-documented, the mechanistic links between aging hallmarks and disease-specific vulnerability remain poorly understood. This page ranks 20 critical knowledge gaps at the intersection of aging biology and neurodegeneration, highlighting research directions that could unlock disease-modifying or preventive therapies. ^{1Mattson MP and Magnus T, Ageing and neuronal vulnerability (2006)2006 · PMID 17051205Open reference}

Understanding these gaps is essential because interventions targeting aging itself — rather than individual disease proteins — could potentially delay or prevent multiple neurodegenerative diseases simultaneously. ^{2Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023)2023 · DOI 10.1038/s41591-023-02543-wOpen reference}

Scoring Methodology

Gaps are scored on a 0–10 scale across four dimensions: ^{3An epigenetic biomarker of aging for lifespan and healthspan (2018)2018 · DOI 10.18632/aging.101414Open reference}

• Impact if Solved: Would solving this gap change treatment or prevention of age-related neurodegeneration?

• Tractability: Is this answerable with current or near-term technology?

• Under-exploration: Are too few researchers working on this? (10 = severely under-explored)

• Data Availability: Do relevant datasets, biobanks, or model systems exist?

Total Score: Sum of all four dimensions (max 40) ^{4Blood-brain barrier breakdown in the aging human hippocampus (2015)2015 · DOI 10.1016/j.neuron.2014.12.032Open reference}

Tier Classification

• Tier 1 (30–40): Highest priority — critical gaps requiring immediate focus

• Tier 2 (25–29): High priority — important gaps needing attention

• Tier 3 (20–24): Moderate priority — valuable to address

Ranked Knowledge Gaps

Quadrant Analysis

quadrantChart
 title Aging Research Priorities: Impact vs Tractability
 x-axis Low Tractability --> HighTractability
 y-axis Low Impact --> HighImpact
 quadrant-1 High Priority
 quadrant-2 Watch List
 quadrant-3 Lower Priority
 quadrant-4 Consider Later
    Neuronal vulnerability: [0.7, 0.9]
    Senolytic CNS safety: [0.8, 0.85]
    Epigenetic clocks: [0.8, 0.8]
    BBB aging: [0.7, 0.75]
    Microglial aging: [0.7, 0.75]
    mtDNA damage: [0.7, 0.65]
    Proteostasis collapse: [0.6, 0.7]
    Stem cell exhaustion: [0.7, 0.6]
    NAD decline: [0.8, 0.55]
    mTOR dysregulation: [0.7, 0.55]
    SASP in brain: [0.65, 0.55]
    Partial reprogramming: [0.5, 0.65]

Top 5 Gaps: Deep Analysis

1. Selective Neuronal Vulnerability to Aging (Score: 31)

Current State: Different neuronal populations age at dramatically different rates. Dopaminergic neurons in the substantia nigra, cholinergic neurons in the basal forebrain, and entorhinal cortex layer II neurons are disproportionately vulnerable to age-related degeneration, while many other neuronal types remain remarkably resilient into the tenth decade of life [1]. Single-cell transcriptomics has begun to catalog cell-type-specific aging signatures, but the causal mechanisms remain unknown.

Knowledge Gap: Why do specific neuronal subtypes fail with age while neighboring cells survive? Is vulnerability determined by metabolic load, calcium handling capacity, axonal length, neurotransmitter type, or some combination? Understanding this would explain why Parkinson’s disease affects dopaminergic neurons while Alzheimer’s disease preferentially targets cholinergic neurons and cortical pyramids.

What Would It Take to Solve This:

• Large-scale single-cell multi-omic profiling (transcriptome + epigenome + proteome) across neuronal subtypes at multiple ages

• Development of in vivo reporters for cellular stress in specific neuron types

• Computational models integrating metabolic demand, mitochondrial capacity, and repair mechanisms per cell type

• Comparison of vulnerable vs. resilient neurons within the same brain, controlling for environment

Cross-Disease Relevance: Solving this gap would illuminate vulnerability patterns in Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease simultaneously.

2. Senolytic Safety and Efficacy in the CNS (Score: 31)

Current State: Senolytics — drugs that selectively eliminate senescent cells — have shown dramatic benefits in peripheral tissues and in mouse models of neurodegeneration. Dasatinib + quercetin (D+Q) reduced tau pathology and improved cognition in PS19 tau mice, and cleared senescent astrocytes and microglia [2]. The SASP produced by senescent glia drives chronic neuroinflammation that accelerates neurodegeneration.

Knowledge Gap: It is unclear which senescent cell types in the aging brain are most damaging, whether eliminating them is safe long-term (some senescent cells may have protective roles in wound healing or tumor suppression), and whether systemically administered senolytics achieve sufficient CNS penetration. No large human trial has tested senolytics for neurodegeneration.

What Would It Take to Solve This:

• Cell-type-specific senescence reporters in the human brain (identify senescent microglia, astrocytes, oligodendrocytes, and neurons separately)

• BBB-penetrant senolytic molecules or targeted delivery strategies

• Phase I/II trials with CNS biomarker endpoints (CSF SASP factors, PET imaging of senescence)

• Long-term safety studies assessing whether clearing senescent neurons causes circuit damage

Cross-Disease Relevance: Senescent glia accumulate in Alzheimer’s, Parkinson’s, ALS, and normal aging — a successful senolytic strategy could benefit all.

3. Epigenetic Clocks as Causal vs. Correlative Markers (Score: 31)

Current State: DNA methylation-based epigenetic clocks (Horvath, GrimAge, DunedinPACE) robustly predict biological age and mortality, and accelerated epigenetic aging correlates with cognitive decline and dementia risk [3]. Brain-specific clocks show accelerated aging in Alzheimer’s hippocampus and Parkinson’s substantia nigra. Epigenetic reprogramming via Yamanaka factors (OSKM) can reverse epigenetic age in vitro.

Knowledge Gap: Are the methylation changes measured by epigenetic clocks causally driving cellular dysfunction, or are they merely downstream markers of other aging processes? If causal, which specific CpG sites matter most for neuronal health? Can targeted epigenetic editing at key loci rejuvenate aged neurons without oncogenic risk?

What Would It Take to Solve This:

• CRISPR-based epigenetic editing at specific clock CpGs to test causality

• Single-cell epigenetic profiling of aging human brain at high resolution

• Conditional, cell-type-specific partial reprogramming in animal models with long-term safety monitoring

• Identification of “rejuvenation CpGs” vs. “bystander CpGs” in epigenetic clocks

4. Blood-Brain Barrier Aging and Permeability (Score: 29)

Current State: The BBB progressively deteriorates with age, with increased permeability detectable by DCE-MRI in humans over 60. Age-related loss of pericytes, breakdown of tight junction proteins, and reduced efflux transporter function allow plasma proteins (including fibrinogen, albumin, and autoantibodies) to enter the brain parenchyma [4]. This triggers microglial activation and neuroinflammation.

Knowledge Gap: The molecular mechanisms driving BBB aging are incompletely mapped. It is unknown whether BBB breakdown is a primary driver of neurodegeneration or a secondary consequence. We lack interventions to specifically restore BBB integrity in the aging brain. Parabiosis experiments showing young blood factors rejuvenate old brains implicate circulating factors, but the identity of all relevant factors and their BBB targets remains elusive.

What Would It Take to Solve This:

• Comprehensive proteomic profiling of aging BBB endothelial cells and pericytes

• Identification of druggable targets that restore tight junction integrity

• Clinical trials testing BBB-restorative interventions with DCE-MRI endpoints

• Determination of whether BBB restoration alone can slow cognitive decline

Cross-Disease Relevance: BBB breakdown is observed in Alzheimer’s, Parkinson’s, ALS, and vascular dementia.

5. Microglial Aging and Immune Memory (Score: 29)

Current State: Microglia undergo profound changes with aging, developing a “dystrophic” phenotype characterized by fragmented processes, increased SASP factor secretion, impaired phagocytosis, and accumulation of lipid droplets [5]. Aged microglia also exhibit “trained immunity” — long-lasting pro-inflammatory epigenetic reprogramming triggered by peripheral infections or systemic inflammation.

Knowledge Gap: How do aged microglia differ from disease-associated microglia (DAM)? Can dystrophic microglia be rejuvenated through CSF1R inhibitor-mediated turnover, or do replacement microglia also rapidly adopt a dystrophic phenotype in the aged brain milieu? Does microglial immune memory from early-life infections (via NLRP3 inflammasome priming) determine individual risk for late-life neurodegeneration?

What Would It Take to Solve This:

• Longitudinal single-cell profiling of microglia across the human lifespan

• CSF1R inhibitor trials specifically targeting microglial turnover in aged individuals

• Epigenetic profiling of “trained” vs. “naive” microglia across ages

• Studies linking early-life infection history to late-life microglial phenotype and dementia risk

Gaps 6–20: Summary Analysis

6. Mitochondrial DNA Damage Accumulation in Neurons (Score: 28)

Post-mitotic neurons accumulate mitochondrial DNA mutations at approximately 10 times the rate of nuclear DNA. Clonal expansion of deleterious mtDNA mutations leads to respiratory chain deficiency, particularly in dopaminergic neurons of the substantia nigra [6]. The threshold at which mtDNA heteroplasmy becomes functionally damaging in each neuronal subtype is unknown, as are the mechanisms governing selective expansion of mutant mtDNA.

7. Proteostasis Network Collapse Timing (Score: 28)

The ubiquitin-proteasome system, autophagy-lysosomal pathway, and chaperone networks decline with age, but whether this decline is gradual or involves critical threshold transitions is unknown [7]. Understanding the tipping point where proteostasis fails could enable early intervention before aggregation cascades become irreversible in Alzheimer’s (amyloid/tau) and Parkinson’s (alpha-synuclein).

8. Neural Stem Cell Exhaustion Mechanisms (Score: 28)

Adult neurogenesis declines dramatically with age, particularly in the hippocampal dentate gyrus. Whether this reflects quiescence, senescence, niche deterioration, or true stem cell depletion is debated [8]. Strategies to reactivate or replace aged neural stem cells could restore cognitive reserve.

9. NAD+ Decline and Sirtuin Dysfunction (Score: 28)

Brain NAD+ levels decline approximately 50% between youth and old age, compromising sirtuin activity, DNA repair (via PARP), and mitochondrial function. NMN and NR supplementation restore NAD+ in animal models, but human CNS bioavailability and optimal dosing remain unclear [9]. The relative contributions of decreased synthesis, increased consumption (CD38 upregulation), and impaired recycling are debated.

10. mTOR Dysregulation in Brain Aging (Score: 28)

mTOR signaling increases with brain aging, suppressing autophagy and promoting cellular senescence. Rapamycin extends lifespan across species and reduces neurodegeneration in animal models, but chronic mTOR inhibition risks immunosuppression [10]. The optimal degree and cell-type specificity of mTOR inhibition for neuroprotection is unknown.

11. SASP Composition in the Aging Brain (Score: 27)

The SASP secreted by senescent brain cells includes hundreds of cytokines, chemokines, proteases, and growth factors. Brain SASP likely differs from peripheral SASP, but its full composition across cell types is uncharacterized [11]. Identifying the most neurotoxic SASP components could enable targeted neutralization without eliminating potentially beneficial senescent cells.

12. Partial Reprogramming Safety in Post-Mitotic Neurons (Score: 26)

Transient expression of Yamanaka factors (OSKM) can reverse epigenetic clocks age markers in cells without dedifferentiation, a process called partial reprogramming. In neurons, this raises unique safety concerns — a post-mitotic cell cannot tolerate any cell cycle re-entry [12]. Developing neuron-safe reprogramming protocols is among the most ambitious rejuvenation strategies.

13. Sleep Disruption as Aging Accelerator (Score: 26)

Sleep quality declines with age, reducing glymphatic clearance of waste products including amyloid-beta and tau. Whether age-related sleep disruption actively accelerates neurodegeneration (and is thus a modifiable risk factor) or is merely a symptom remains debated [13]. Interventions restoring slow-wave sleep in the elderly could be neuroprotective.

14. Telomere Dysfunction in Non-Dividing Neurons (Score: 26)

While telomere attrition primarily affects dividing cells, post-mitotic neurons also accumulate telomere damage through oxidative stress, activating DNA damage responses that drive senescence-like phenotypes without cell division [14]. The functional significance of telomere damage in neurons versus glia is poorly defined.

15. Gut-Brain Axis Changes with Aging (Score: 25)

Age-related gut microbiome dysbiosis increases intestinal permeability and systemic inflammation. In animal models, transferring young microbiota to aged mice improves cognition and reduces neuroinflammation [15]. Mechanisms linking specific microbial species or metabolites to brain aging, and whether probiotic or FMT interventions could delay neurodegeneration in humans, are unclear.

16. Vascular Aging and Neurovascular Unit Decline (Score: 25)

The neurovascular unit — comprising endothelial cells, pericytes, astrocyte endfeet, and smooth muscle — deteriorates with aging, reducing cerebral blood flow by approximately 0.5% per year after age 30. This chronic hypoperfusion compounds metabolic stress on energy-demanding neurons, but the relative contribution of vascular vs. cell-autonomous aging to neurodegeneration is unknown.

17. Caloric Restriction Mimetics for Neuroprotection (Score: 25)

Caloric restriction (CR) is the most robust intervention extending lifespan across species and delays age-related neurodegeneration in animal models. CR mimetics (metformin, resveratrol, spermidine) activate sirtuin and AMPK pathways, but human evidence for neuroprotection is limited. The TAME trial (metformin for aging) is ongoing but has no CNS endpoints.

18. Age-Related Loss of Synaptic Plasticity (Score: 24)

Synaptic density and long-term potentiation (LTP) decline with age before overt neurodegeneration. The molecular mechanisms — reduced BDNF, altered calcium homeostasis, epigenetic changes at plasticity genes — are individually characterized but their integration and relative importance are unknown. Whether synaptic loss is a cause or consequence of aging pathology remains contested.

19. White Matter Aging and Oligodendrocyte Decline (Score: 24)

White matter volume peaks around age 40 and declines thereafter, driven by oligodendrocyte death, demyelination, and impaired remyelination. Oligodendrocyte precursor cells (OPCs) become less responsive to differentiation signals with age. White matter changes may disconnect neural circuits and contribute to cognitive decline independently of gray matter pathology.

20. Sex Differences in Brain Aging Trajectories (Score: 24)

Women have higher lifetime risk of Alzheimer’s disease, while men have higher risk of Parkinson’s disease. Post-menopausal estrogen decline, X-chromosome effects, microglial sex differences, and hormonal influences on APOE expression create sex-specific aging trajectories [16]. Most aging studies use predominantly male animals, leaving sex-specific mechanisms severely under-researched.

Cross-Disease Connections

++ = high relevance, + = moderate relevance, — = low relevance

Recent Advances (2024–2026)

• Epigenetic reprogramming: Yamanaka factor-based partial reprogramming in aged mouse neurons reversed age-related transcriptomic signatures and improved memory, without teratoma formation, raising hopes for clinical translation [12]

• Senolytic clinical trials: The SToMP-AD trial (dasatinib + quercetin in early Alzheimer’s) demonstrated BBB penetration and CSF senescence biomarker reduction in the phase I/II study [2]

• GLP-1 agonists: Large observational studies link semaglutide use to 40–70% reduced risk of Alzheimer’s and Parkinson’s diagnoses, with prospective trials underway

• Young plasma factors: GPLD1 and clusterin from young blood improve hippocampal neurogenesis in aged mice; clinical trials of plasma exchange/dilution showed preliminary cognitive benefits

• Microbiome interventions: FMT from young to aged mice restored hippocampal neurogenesis and reduced neuroinflammation, spurring human trials

Pathway Diagram

The following diagram shows the key molecular relationships involving Aging and Rejuvenation Knowledge Gaps discovered through SciDEX knowledge graph analysis:

graph TD
    PARKINSON["PARKINSON"] -->|"associated with"| AGING["AGING"]
    CANCER["CANCER"] -->|"associated with"| AGING["AGING"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| AGING["AGING"]
    APOPTOSIS["APOPTOSIS"] -->|"activates"| AGING["AGING"]
    PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] -->|"associated with"| AGING["AGING"]
    ALZHEIMER["ALZHEIMER"] -->|"associated with"| AGING["AGING"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"causes"| AGING["AGING"]
    NAD["NAD"] -->|"activates"| AGING["AGING"]
    MITOCHONDRIAL_DYSFUNCTION["MITOCHONDRIAL DYSFUNCTION"] -->|"activates"| AGING["AGING"]
    INFLAMMATION["INFLAMMATION"] -->|"associated with"| AGING["AGING"]
    AUTOPHAGY["AUTOPHAGY"] -->|"associated with"| AGING["AGING"]
    OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"activates"| AGING["AGING"]
    AUTOPHAGY["AUTOPHAGY"] -->|"regulates"| AGING["AGING"]
    ALZHEIMER["ALZHEIMER"] -->|"causes"| AGING["AGING"]
    NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"] -->|"regulates"| AGING["AGING"]
    style PARKINSON fill:#ce93d8,stroke:#333,color:#000
    style AGING fill:#ce93d8,stroke:#333,color:#000
    style CANCER fill:#ce93d8,stroke:#333,color:#000
    style ALZHEIMER_S_DISEASE fill:#ce93d8,stroke:#333,color:#000
    style APOPTOSIS fill:#ce93d8,stroke:#333,color:#000
    style PARKINSON_S_DISEASE fill:#ce93d8,stroke:#333,color:#000
    style ALZHEIMER fill:#ce93d8,stroke:#333,color:#000
    style NAD fill:#ce93d8,stroke:#333,color:#000
    style MITOCHONDRIAL_DYSFUNCTION fill:#ce93d8,stroke:#333,color:#000
    style INFLAMMATION fill:#4fc3f7,stroke:#333,color:#000
    style AUTOPHAGY fill:#81c784,stroke:#333,color:#000
    style OXIDATIVE_STRESS fill:#ce93d8,stroke:#333,color:#000
    style NEURODEGENERATIVE_DISEASES fill:#ce93d8,stroke:#333,color:#000